Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;29(4):424-31.
doi: 10.1016/j.healun.2009.08.029. Epub 2009 Oct 22.

The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation

Matthew R Morrell  1 , George J Despotis, Douglas M Lublin, George A Patterson, Elbert P Trulock, Ramsey R Hachem
Affiliations

The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation

Matthew R Morrell et al. J Heart Lung Transplant. 2010 Apr.

Abstract

Background: Extracorporeal photopheresis (ECP) has been used to treat acute and chronic rejection after solid organ transplantation. However, data supporting the use of ECP for bronchiolitis obliterans syndrome (BOS) after lung transplantation are limited.

Methods: We retrospectively analyzed the efficacy and safety of ECP for progressive BOS at our institution. Between January 1, 2000, and December 31, 2007, 60 lung allograft recipients were treated with ECP for progressive BOS.

Results: During the 6-month period before the initiation of ECP, the average rate of decline in forced expiratory volume in 1 second (FEV(1)) was -116.0 ml/month, but the slope decreased to -28.9 ml/month during the 6-month period after the initiation of ECP, and the mean difference in the rate of decline was 87.1 ml/month (95% confidence interval, 57.3-116.9; p < 0.0001). The FEV(1) improved in 25.0% of patients after the initiation of ECP, with a mean increase of 20.1 ml/month.

Conclusions: ECP is associated with a reduction in the rate of decline in lung function associated with progressive BOS.

PubMed Disclaimer

Comment in

MeSH terms